Business UpdateJun 10, 2026, 08:56 AM
Mesoblast Ryoncil Net Revenue Exceeds $100M Since Launch
AI Summary
Mesoblast announced the successful commercial launch of Ryoncil, with net revenue exceeding US$100M since its introduction. The product generated US$35.3M in gross revenue and US$30.3M in net revenue for Q3 FY26, contributing US$44.2M in gross profit for 1H FY26. The company is leveraging Ryoncil's profitability to fund its growth pipeline, which includes three additional major Phase 3 assets and label extension studies for Ryoncil.
Key Highlights
- Mesoblast's Ryoncil net revenue exceeded US$100M since its launch.
- Ryoncil's Q3 FY26 gross revenue was US$35.3M, with net revenue of US$30.3M.
- Ryoncil's gross profit for 1H FY26, excluding amortization, was US$44.2M.
- The company holds over 1,100 patents and applications, with protection extending to at least 2044.
- Mesoblast has three additional major Phase 3 assets in its pipeline.
- Pipeline includes Phase 3 programs for rexlemestrocel-L in low back pain and inflammatory heart failure.
- Phase 3 programs aim to extend Ryoncil's label to adult aGvHD and pediatric rare diseases.
Price Impact
More from MESO